AstraZeneca PLC ADR ZEGA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ZEGA is a good fit for your portfolio.
News
-
AstraZeneca Executives' Compensation Policy Passes With Low Shareholder Approval
-
AstraZeneca Raises Dividend
-
Trending: Astrazeneca Aims to Accelerate Cancer Treatment Development With $2.4 Billion Fusion Deal
-
Don't want to chase Big Tech? Money manager flags three unloved stocks to bet on now.
-
Fusion Pharmaceuticals Shares Soar Premarket on AstraZeneca Deal
-
AstraZeneca Buys Fusion for Up to $2.4 Billion — Update
-
AstraZeneca Buys Fusion for Initial $2 Billion
-
AstraZeneca strikes $1 billion deal for rare-disease drug maker
Trading Information
- Previous Close Price
- $65.50
- Day Range
- $65.00–65.50
- 52-Week Range
- $38.60–70.50
- Bid/Ask
- $65.00 / $66.50
- Market Cap
- $201.53 Bil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- 19.55
- Price/Sales
- 4.83
- Dividend Yield (Trailing)
- 2.05%
- Dividend Yield (Forward)
- 2.05%
- Total Yield
- 2.05%
Company Profile
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Growth
- Total Number of Employees
- 89,900
- Website
- https://www.astrazeneca.com
Competitors
Valuation
|
Metric
|
ZEGA
|
LLY
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 19.55 | 87.16 | 84.62 |
Price/Book Value | 5.73 | 64.46 | 8.55 |
Price/Sales | 4.83 | 19.36 | 5.38 |
Price/Cash Flow | 22.04 | 90.55 | 21.26 |
Price/Earnings
ZEGA
LLY
MRK
Financial Strength
|
Metric
|
ZEGA
|
LLY
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.58 | 0.52 | 0.68 |
Current Ratio | 0.82 | 0.94 | 1.25 |
Interest Coverage | 5.15 | 14.13 | 2.33 |
Quick Ratio
ZEGA
LLY
MRK
Profitability
|
Metric
|
ZEGA
|
LLY
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 11.55% | 10.22% | 3.59% |
Return on Equity (Normalized) | 30.14% | 52.03% | 9.12% |
Return on Invested Capital (Normalized) | 18.47% | 19.27% | 5.88% |
Return on Assets
ZEGA
LLY
MRK
Drug Manufacturers - General Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Ghtzyjlnj | Zxrx | $695.3 Bil | |
JNJ
| Johnson & Johnson | Crvjpvjs | Rxfk | $359.3 Bil | |
MRK
| Merck & Co Inc | Mhlztsq | Jxkp | $321.5 Bil | |
ABBV
| AbbVie Inc | Nmdvqyv | Dlqhl | $297.3 Bil | |
AZN
| AstraZeneca PLC ADR | Spclbtfp | Clp | $215.8 Bil | |
RHHBY
| Roche Holding AG ADR | Kytxlwtl | Xfmr | $199.7 Bil | |
NVS
| Novartis AG ADR | Hclwzyyrv | Lmnwd | $196.0 Bil | |
PFE
| Pfizer Inc | Jcqvlsmxt | Rvqz | $148.7 Bil | |
AMGN
| Amgen Inc | Vttqlngg | Bbvsw | $145.8 Bil | |
SNY
| Sanofi SA ADR | Mlncfwd | Tyvq | $117.3 Bil |